---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Care management intervention strategies"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Care management intervention strategies. Topics: Monitoring for conversion to neovascular AMD during complement inhibitor therapy, Self-monitoring and electronic home monitoring, Follow-up visits: history and examination, Patient education and shared decision-making, and 1 further topic. 5 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Monitoring for conversion to neovascular AMD during complement inhibitor therapy

> “Because of the risk of exudative AMD, patients should be monitored and treated if needed.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “If an eye develops nAMD during GA treatment, nAMD treatment will need to be initiated if there are signs of exudation in the macula.”
> “Combined GA and nAMD treatment is both feasible and safe based on pivotal clinical trials, but injections may need to be provided either on different clinical visits or separated by approximately 30 min if performed on the same day to minimize the risk of excessive intraocular pressure elevation.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.2.4-2"></a>

### Self-monitoring and electronic home monitoring

> “Patients with a high-risk AMD phenotype are at increased risk of progression to advanced AMD and should be educated about methods of detecting new symptoms of MNV, including self-monitoring.”
> “Electronic monitoring devices are now available to aid in the detection of neovascularization at an early stage.”
> “Since some patients with AMD also have cognitive impairment, a family member or care assistant should prompt the patient to self-test.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “Additionally, it is suggested that the patient consider self-monitoring between visits using Amsler grid testing or with the use of preferential hyperacuity perimetry home testing.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.2.4-3"></a>

### Follow-up visits: history and examination

> “A history and examination are the recommended elements of the follow-up visits, and the recommended follow-up intervals are listed in Table 6.”
> “Changes in medications and nutritional supplements”
> “Visual acuity at distance with correction”
> “Stereoscopic biomicroscopic examination of the fundus”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “As with many diseases, the severity and rate of progression will vary from patient to patient. Therefore, adjustments to follow-up frequency should be considered depending on the identification of signs of increased risk, such as advanced age, family history, smoking history, and whether the patient is monocular.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.2.4-4"></a>

### Patient education and shared decision-making

> “The physician should discuss the use of these medications with the patient, based on individual circumstances, including documented treatment benefits and risks.”
> “All patients with AMD should be educated about the prognosis of the disease and the potential value of treatment as appropriate for their visual and functional status.”
> “Patients can be informed that while central visual loss is common, total visual loss is extremely rare.”
> “Insofar as cigarette smoking is a key modifiable risk factor, smoking cessation is strongly recommended when advising patients with AMD or at risk for AMD.”

Source: [Vemulakonda et al. (2025)](https://www.aao.org/Assets/f832e5ac-c047-4d1c-bdab-c5e52173623d/638760137410500000/age-related-macular-degeneration-ppp-pdf)

> “Additionally, the physician should educate the patient with regard to GA progression and treatment expectations.”
> “Additionally, the treating physician should educate patients on symptoms that may signify occurrence of adverse events, such as pain, new visual changes, or new floaters.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

<a id="topic-2.2.2.4-5"></a>

### Treatment selection and discontinuation for approved complement inhibitors

> “In general, treatment decisions are influenced by patient symptoms, visual acuity, age, fellow-eye status, and ocular comorbidities, as well as the discretion of the physician and patient to conduct a comprehensive personalized risk-benefit assessment that is guided by a general evidence-based treatment algorithm.”
> “Several circumstances may warrant discontinuation of GA treatment, such as the occurrence of severe adverse events including endophthalmitis, ischemic optic neuropathy, sustained elevation of intraocular pressure, and significant, nontransient intraocular inflammation, especially if associated with any retinal vasculitis or occlusive vasculitis.”
> “Additionally, severe central vision loss may represent a scenario where ongoing treatment risks or burdens may not significantly outweigh any potential benefits.”

Source: [Regillo et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10850989/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
